The successful presence of Pars Isotope at the 9th International Congress and the 19th Annual Congress of Clinical Oncology

Pars Isotope participated in the 9th International Congress and 19th Annual Congress of Clinical Oncology, which was held at the Olympic Hotel from January 29 to 31, 2025. Pars Isotope’s stand was well received by visitors at this important scientific event.

Our advanced products, especially Ga-68-FAPI and Lu-177-FAPI, which are used for the diagnosis and treatment of more than 30 types of cancer, attracted the attention of many radiation oncologists, students, and professors. Radiation oncologists expressed interest in using these products as innovative and advanced methods in cancer diagnosis and treatment in the field of oncology. Additionally, students and professors expressed interest in research collaborations with Pars Isotope.

Among the distinguished visitors to Pars Isotope’s stand was Dr. Makhdoomi, the President of the Iranian Society of Radiation Oncology, who considered Pars Isotope’s presence at this congress a valuable opportunity and introduced the company as a pioneer and influential player in community health. He also expressed hope to organize seminars and educational events for oncologists in collaboration with Pars Isotope in the future.

In addition, the Ambassador of Turkmenistan to Iran visited Pars Isotope’s stand and found the company’s products and services highly appealing.

Pars Isotope’s participation in this congress was not only an opportunity to showcase advanced products in cancer diagnosis and treatment but also a foundation for broader scientific and research collaborations in the future. As the sole producer and supplier of diagnostic and therapeutic radiopharmaceuticals in Iran, Pars Isotope continues to take steps toward advancing treatment and innovative technologies in this field.